Researchers are testing a new drug, ASP5834, for people with solid tumors. Tumors are abnormal growths of tissue, and "solid" means they aren't liquid like blood. Some people's tumors have changes in a gene called KRAS, which can make the tumor grow. ASP5834 aims to target these changes. In the study, some participants with colorectal cancer will also receive a drug called panitumumab, which is already used for this cancer.
The study checks how ASP5834 affects the body and its safety. It's an open-label study, meaning everyone knows who gets which treatment. There are two parts: finding the right dose and testing that dose. Participants will get treatments through a needle in a vein, called an infusion, which happens every 21 or 28 days.
- Study lasts about 1 year, with visits to the clinic for health checks and scans.
- Only adults with specific KRAS mutations and no other serious health issues can join.
- Participants can't join if they have certain heart issues, other cancers, or recent serious health events.
How understandable was the trial content above?
Hard to understand
Easy to understand